shutterstock_1155148972_atmosphere1

Atmosphere1 / Shutterstock.com

5 April 2022GenericsAlex Baldwin

MSD targets Mankind’s diabetes generic in patent suit

Merck Sharp & Dohme (known as MSD outside the US) has filed a complaint against New Dehli-based Mankind Pharma, looking to halt the approval of a generic version of the type two diabetes treatment, Januvia (Sitagliptin).

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

MSD, Pfizer try to stop three Steglatro generics

29 March 2022 Merck Sharp & Dohme and Pfizer have filed three complaints with the Delaware district court to attempt to shut down proposed generics of Steglatro—a diabetes treatment that Pfizer licences to MSD.

AstraZeneca, MSD sue MSN and Sandoz over Calquence generics

8 February 2022 AstraZeneca and Merck, Sharp & Dohme have filed a pair of lawsuits against MSN and Sandoz, claiming their planned generic versions of its leukaemia treatment Calquence infringe six patents.

More on this story

MSD, Pfizer try to stop three Steglatro generics

29 March 2022 Merck Sharp & Dohme and Pfizer have filed three complaints with the Delaware district court to attempt to shut down proposed generics of Steglatro—a diabetes treatment that Pfizer licences to MSD.

AstraZeneca, MSD sue MSN and Sandoz over Calquence generics

8 February 2022 AstraZeneca and Merck, Sharp & Dohme have filed a pair of lawsuits against MSN and Sandoz, claiming their planned generic versions of its leukaemia treatment Calquence infringe six patents.

More on this story

MSD, Pfizer try to stop three Steglatro generics

29 March 2022 Merck Sharp & Dohme and Pfizer have filed three complaints with the Delaware district court to attempt to shut down proposed generics of Steglatro—a diabetes treatment that Pfizer licences to MSD.

AstraZeneca, MSD sue MSN and Sandoz over Calquence generics

8 February 2022 AstraZeneca and Merck, Sharp & Dohme have filed a pair of lawsuits against MSN and Sandoz, claiming their planned generic versions of its leukaemia treatment Calquence infringe six patents.

More features

Patent attorneys by day, coders by night: Sterne Kessler launches ‘homemade’ AI assistant

Mental health IP toolkit: Diversity Champ’s stress-busting tips

Eli Lilly piles on weight loss drug suits to ward off revenue squeeze

Patent cliff: 5 blockbusters running out of road

Herbert Smith Freehills expands German tech patent team

‘Always new twists’: Bayer legal team on defending a $4bn drug

Novartis and MSN feud intensifies after Fed Circ denies rehearing

EU court signals tough stance on ‘pay-for-delay’ pharma deals